Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date	Title and Summary	View
Jun 20, 2022	PTC Therapeutics to Host Call to Review Topline Results from Study 041 for Translarna™ (ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy SOUTH PLAINFIELD, N.J. , June 20, 2022 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) will host a conference call Tuesday, June 21 st at 8:00 a.m. E.T. to review topline results from Study 041 of Translarna™ (ataluren) in patients with nonsense mutation Duchenne muscular dystrophy.	Additional Formats
Jun 09, 2022	Biotech Investment Veteran Alethia Young Joins PTC Therapeutics' Board of Directors SOUTH PLAINFIELD, N.J. , June 9, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Alethia Young to the company's Board of Directors. Ms. Young has more than 20 years of experience in healthcare and biotech equity research and investing.	Additional Formats
Jun 06, 2022	PTC Therapeutics to Participate at William Blair 42nd Annual Growth Stock Conference SOUTH PLAINFIELD, N.J. , June 6, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the William Blair 42 nd Annual Growth Stock Conference on Thursday, June 9 at 2:20 p.m. ET The presentation will be webcast live on the	Additional Formats
Jun 03, 2022	Preliminary Results Presented at ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study - Results highlight strength of PTC Therapeutics' scientific platform in targeting difficult-to-treat rare cancer types - SOUTH PLAINFIELD, N.J. , June 3, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced encouraging preliminary safety and efficacy results from its Phase 1B	Additional Formats
May 31, 2022	FDA Approves Label Extension for Evrysdi® for Infants with Spinal Muscular Atrophy Under 2 Months Old - Evrysdi is the first and only at-home administered treatment for patients living with SMA - - Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date - SOUTH PLAINFIELD, N.J. , May 31, 2022 /PRNewswire/ -- PTC Therapeutics, Inc.	Additional Formats
May 20, 2022	PTC Therapeutics Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency – First ever gene therapy directly administered into the brain – – Recommended for regulatory approval by EMA – – Results demonstrated sustained improvements in motor and cognitive function – – Conference call scheduled for Monday, May 23 , at 8 a.m. ET – SOUTH PLAINFIELD, N.J.	Additional Formats
May 03, 2022	PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results - $149 million total revenue representing impressive 26% year-over-year growth – - Initiation of PIVOT-HD Phase 2 trial of PTC518 in Huntington's disease – - CHMP opinion on AADC gene therapy expected in May; ready to execute on potential launch – SOUTH PLAINFIELD, N.J.	Additional Formats
Apr 29, 2022	PTC Therapeutics to Participate at Upcoming Investor Conferences SOUTH PLAINFIELD, N.J. , April 29, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: Bank of America Securities 2002 Healthcare Conference Tuesday, May 10 at 5:20 p.m.	Additional Formats
Apr 19, 2022	PTC Therapeutics to Host Conference Call to Discuss First Quarter 2022 Financial Results SOUTH PLAINFIELD, N.J. , April 19, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2022 financial results and provide an update on the company's business and outlook on Tuesday, May 3 , at	Additional Formats
Apr 14, 2022	PTC Therapeutics Provides Update on EMA Regulatory Review Timeline For Its AADC Deficiency Gene Therapy Program - CHMP Opinion Now Expected May 2022 - SOUTH PLAINFIELD, N.J. , April 14, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that it has completed the Scientific Advisory Group and Oral Explanation meetings for its gene therapy treatment for AADC deficiency (PTC-AADC) with	Additional Formats